News Release
View printer-friendly version
|
<< Back |
ZUG,
Presentation:Allogeneic chimeric antigen receptor T cells targeting B cell maturation antigen
Session: Adoptive Cell Therapy 1
Time and Date:
Location:
Presentation:Allogeneic CRISPR engineered anti CD70 CAR T cells demonstrate potent preclinical activity against both solid and hematological cancer cells
Session: Adoptive Cell Therapy 2
Time and Date:
Location:
Following presentation at the meeting, the posters will be available on CRISPR Therapeutics’ website at http://www.crisprtx.com.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. The Company has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge,
CONTACTS
Investors:
617-307-7227
chris.erdman@crisprtx.com
or
339-970-2843
chris.brinzey@westwicke.com
Media:
WCG for CRISPR
347-658-8290
jpaganelli@wcgworld.com
Source: CRISPR Therapeutics AG